MedPath

Is Real-time CGM Superior to Flash Glucose Monitoring in Real Life Study (CORRIDA LIFE)

Not Applicable
Conditions
Diabetes Mellitus, Type 1
Interventions
Device: Continuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring)
Device: Continuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring)
Registration Number
NCT04759495
Lead Sponsor
Charles University, Czech Republic
Brief Summary

The aim of the investigator's study is to compare real-time continuous glucose monitoring (rt-CGM) and flash glucose monitoring (FGM) in adult patients with Type 1 Diabetes (T1D) in real life practice during 24 weeks of follow-up.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
187
Inclusion Criteria
  • patients with T1D naive to rt-CGM and FGM
  • Type 1 diabetes for > 1 year
  • ≥ 18 years old
  • CSII without automatic functions or MDI
Exclusion Criteria
  • previous rtCGM or FGM use
  • treatment with insulin pump with automatic functions
  • severe noncompliance
  • known severe diabetic retinopathy and/or macular edema
  • lactation, pregnancy, or intending to become pregnant during the study
  • a condition likely to require MRI
  • use of acetaminophen-containing medication
  • unwillingness to use the study device for >70% of time

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
rtCGMContinuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring)Patients with use of the DEXCOM G5 or G6 system (real time continuous glucose monitoring).
FGMContinuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring)Patients with use of the FreeStyle Libre Flash system (flash glucose monitoring).
Primary Outcome Measures
NameTimeMethod
Changes in glycated haemoglobin (HbA1c)Up to 13 months

Differences between HbA1c values in the Run in period and after 12 month of follow-up and differences of HbA1c between groups.

Secondary Outcome Measures
NameTimeMethod
Incidence of severe ketoacidosisUp to 13 months

Requiring hospitalization

Percentage of time in hyperglycemic rangesUp to 13 months

\>10.0 mmol/L \[180 mg/dl\] and \>13.9 mmol/L \[250 mg/dl\]

Incidence of skin reaction, infection or hematoma at the site of insertion of the sensorUp to 13 months

Skin reaction, infection or hematoma reported by patients

Percentage of time in hypoglycemic rangesUp to 13 months

\<3.9 mmol/L \[70 mg/dl\] and \<3.0 mmol/L \[54 mg/dl\]

Changes in glycemic variabilityUp to 13 months

Expressed as the standard deviation

Mean sensor glucose concentrationUp to 13 months

Measured by rtCGM or FGM

Incidence of severe hypoglycaemiaUp to 13 months

Requiring third-party assistance to treat

Percentage of time in target rangesUp to 13 months

3.9-10.0 mmol/L \[70-180 mg/dl\]

Trial Locations

Locations (1)

3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University

🇨🇿

Prague, Czechia

© Copyright 2025. All Rights Reserved by MedPath